Skip to content
OpenCapital
Get started

Tenet Healthcare THC Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

Cardinal Health logo
Cardinal HealthCAH
——

Other financials

Income statement

See full
Revenue$5.4B+2.8%
Operating income$1.3B+37.4%
Net income$906.0M+45.7%
EPS (diluted)$8.01+87.6%

Balance sheet

See full
Cash & equivalents$3.0B-1.1%
Total debt$13.3B+0.2%
Total equity$4.8B+15.1%
Total assets$31.2B+6.7%

Cash flow

See full
Operating cash flow$1.6B+101%
CapEx$180.0M+4.0%
Free cash flow$1.5B+128%

Valuation

See full
Market cap$14.86B—
Enterprise value$25.19B—
P/E5.6×—
P/S0.7×—

Profitability

See full
Operating margin18%+0.4pp
Net margin12.4%+0.9pp
FCF margin15.6%—

Returns & leverage

See full
Return on equity58.9%-2.7pp
Debt / equity2.8×-0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Tenet Healthcare in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Tenet Healthcare’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tenet Healthcare's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tenet Healthcare's indefinite-lived research and development assets?
Tenet Healthcare (THC) reported indefinite-lived research and development assets of $884M in Q1 2026.
How has Tenet Healthcare's indefinite-lived research and development assets changed year-over-year?
Tenet Healthcare's indefinite-lived research and development assets increased by 0.2% year-over-year, from $882M to $884M.
What is the long-term trend for Tenet Healthcare's indefinite-lived research and development assets?
Over 3 years (2022 to 2025), Tenet Healthcare's indefinite-lived research and development assets has grown at a 7.3% compound annual growth rate (CAGR), from $714M to $882M.